Introduction
============

End of life care in hospice is expanding globally. For effective hospice care, adequate length of survival (LOS) in hospice is necessary. To improve the LOS in hospice, it is essential that physicians refer patients at the appropriate time, and the hospice team must select the indicated patients for hospice care from the referred patients. If the LOS of the hospice patient is too short, they do not receive adequate help from hospice and their short LOS can have a negative impact on other patients who share the same ward. Therefore, another type of palliative care, such as home hospice care is required for these patients.

Despite some previous reports, there are no established criteria for selection of patients who are more likely to live longer in hospice. Many physicians had a tendency to overestimate the LOS of terminal cancer patients \[[@b1-crt-2013-148],[@b2-crt-2013-148]\]. According to previous studies, there was a considerable physician factor for LOS in hospice; LOS was adequate when the referring physician had previously referred more than two patients to hospice care and estimated patient survival accurately \[[@b3-crt-2013-148]\]. In addition, social factors, local market factors, and accessibility to medical institutions showed an association with early referral to hospice care \[[@b4-crt-2013-148]\]. Significant differences in LOS were observed according to gender, diagnosis, physician specialty, referral source, type of insurance, living status, and discharge status \[[@b5-crt-2013-148]\]. In a recent study, factors showing association with adequate LOS were full-code status, receiving hospice care at home, hospitalization during enrollment in hospice, referral to hospice by an oncologist, and a diagnosis of cancer \[[@b6-crt-2013-148]\].

In this country, no previous study on LOS in hospice and affecting factors has been reported. Therefore, we evaluated the current length of hospice stay and analyzed the patient's factors regarding enrolled time that influenced LOS in hospice.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively examined 446 patients who were admitted to Bucheon St. Mary's Hospital between January 1, 2010, and December 31, 2012. We studied baseline characteristics of these patients. The patients were classified according to age (\< 60, ≥ 60), sex (male, female), partner status (married, or living with a partner; or single, divorced, or widowed), referral hospital (secondary, tertiary), primary diagnosis (gastrointestinal cancer, thoracic cancer, or other cancers), history of chemotherapy (first-line to second-line, more than third-line), ambulation (full, reduced, mainly sitting, mainly supine, totally bedridden), intake (full, reduced, minimal to sips, mouth care only), and consciousness (full, confusion, drowsy to coma). We tried to find the important laboratory results as a prognostic factor. We performed laboratory studies for patients entering hospice. The patients were classified according to the total white blood cell (WBC) count (\< 11,000×10^3^/μL, ≥ 11,000×10^3^/μL), lymphocyte percentage (\< 12%, ≥ 12%), hemoglobin (\< 10 g/dL, ≥ 10 g/dL), platelet (\< 100×10^3^/μL, ≥ 100×10^3^/μL), albumin (\< 3.0 g/dL, ≥ 3.0 g/dL), creatinine (\< 1.5 mg/dL, ≥ 1.5 mg/dL), sodium (\< 135 mmol/L, 135 to 145 mmol/L, \> 145 mmol/L), potassium (\< 3.5 mmol/L, 3.5 to 5.5 mmol/L, \> 5.5 mmol/L), aspa-rtate aminotransferase (AST; \< 100 U/L, ≥ 100 U/L), alanine aminotransferase (ALT; \< 100 U/L, ≥ 100 U/L), total bilirubin (\< 1.0 mg/dL, ≥ 1.0 mg/dL), lactate dehydrogenase (LDH; \< 480, ≥ 480), and C-reactive protein (CRP; \< 5.0 mg/L, ≥ 5.0 mg/L). LOS was the time interval between the day of admission to hospice and the day of the patient's death.

2. Statistical methods
----------------------

The median LOS in hospice and the median referral time to hospice were calculated. Using the Kaplan-Meier method, we analyzed the association between LOS and the patients' baseline demographics (age, sex, marital status, referral hospital, types of cancer, history of chemotherapy), palliative performances (ambulation, intake, consciousness), and laboratory findings (total WBC count, lymphocyte percentage, hemoglobin, platelet, albumin, creatinine, sodium, potassium, AST, ALT, total bilirubin, LDH, CRP). Factors showing significant association with LOS by univariate analysis were evaluated by multivariate analysis using Cox proportional-hazards regression for identification of factors showing independent association with LOS. Analysis was performed using the SPSS ver. 20.0 software package (SPSS Inc., Chicago, IL).

Results
=======

1. Baseline characteristics of patients
---------------------------------------

The median age of the hospice patients was 66 years (range, 13 to 94 years). The baseline demographics of the patients treated at our hospice center are shown in [Table 1](#t1-crt-2013-148){ref-type="table"}; 299 patients (67%) were \> 60 years old, 232 patients (52%) were male; 407 patients (91.3%) were not living with their spouse or a partner (they were single, divorced, or widowed); 214 patients (47.8%) were referred by a tertiary hospital; and 232 patients (51.8%) were referred by a secondary hospital. The primary diagnosis was gastrointestinal cancer in 254 patients (56.7%), thoracic cancer in 102 patients (22.8%), and other cancers in 90 patients (20.1%). Three hundred fifty patients (78.5%) had previously received first-line to second-line chemotherapy before and 96 patients (21.5%) had received more than third-line chemotherapy. At the time of admission to hospice, 112 patients (25.2%) were completely bedridden, 110 patients (24.8%) had mouth care only without intake, and 134 patients (30.1%) had decreased consciousness such as confusion or drowsy to coma. The classifications of the patients according to laboratory results are shown in [Table 1](#t1-crt-2013-148){ref-type="table"}. All patients agreed to an informed consent for 'do not resuscitate' (DNR).

2. Referral time to hospice and LOS in hospice
----------------------------------------------

The median time interval between diagnosis of stage IV or recurrent cancer and referral to hospice was 248 days (range, 1 to 4,405 days). The median time interval between the last day of anticancer treatment and the day of hospice admission was 75 days (range, 3 to 1,310 days). The median LOS was 9.5 days (range, 1 to 186 days) ([Table 2](#t2-crt-2013-148){ref-type="table"}). The LOS of 389 patients (86.8%) was less than one month.

3. Factors affecting LOS in hospice
-----------------------------------

In univariate analysis, factors showing significant association with LOS included sex (p=0.027), intake (p \< 0.02), consciousness (p \< 0.01), total WBC (p \< 0.001), lymphocyte percentage (p \< 0.001), platelet (p=0.006), creatinine (p=0.02), potassium (p=0.004), AST (p \< 0.001), ALT (p \< 0.001), total bilirubin (p \< 0.001), and LDH (p \< 0.001) ([Table 3](#t3-crt-2013-148){ref-type="table"}). In ambulation status, no statistical significance was observed between 'full' and 'reduced' (p=0.146). Age, partner status, referral hospital, primary diagnosis, history of chemotherapy, hemoglobin, albumin, sodium, potassium, and CRP level did not show a statistically significant result.

In multivariate analysis, factors showing significant association with LOS, included intake (p \< 0.05), total WBC (p\<0.001), platelet (p=0.015), creatinine (p=0.007), AST (p=0.03), ALT (p=0.008), and LDH (p=0.006) ([Table 4](#t4-crt-2013-148){ref-type="table"}). As the intake status becomes gradually worse to reduced, minimal to sips, mouth care only, the hazard ratio of short LOS in hospice was increased (hazard ratio, 1.525, 2.096, 2.732). In multivariate analysis, sex, consciousness, lymphocyte percentage, potassium, and total bilirubin did not show a statistically significant result.

Discussion
==========

End of life care for terminal cancer patients is very important and terminal care in hospice is becoming universal. Although LOS in hospice does not show exact correlation with the quality of care, LOS has an important influence on the effect of hospice treatment. There is general agreement among experts in the field and referring clinicians that patients who are referred near the end of life receive fewer benefits from the services that hospice offers. Thus, there is a widespread consensus among experts, referring clinicians, and government agencies that many patients should be enrolled in hospice sooner \[[@b7-crt-2013-148]-[@b10-crt-2013-148]\]. Because there was little information on LOS in hospice and the factors affecting LOS in South Korea, we conducted this study.

At the time of admission to hospice, 112 patients (25%) were completely bedridden, corresponding to below 30% of the Palliative Performance Scale (PPS) ver. 2. Similarly, 110 patients (24.6%) had mouth care only without intake, below 10% of the PPS. In addition, 134 patients (30.6%) had decreased consciousness from confusion to coma, below 10% of the PPS. These results indicate that the palliative performance of these patients was poorer than reported from previous studies of hospices from other countries \[[@b11-crt-2013-148],[@b12-crt-2013-148]\].

Compared with other studies, we found a relatively longer time period (median, 75 days) from the last anticancer treatment to referral to hospice. In addition, the median LOS in hospice was 9.5 days (range, 1 to 186 days), significantly shorter than that reported in another study \[[@b13-crt-2013-148]\]. Reasons for the late referrals could be multiline chemotherapy and longer duration of anticancer treatment. In addition, insufficient in-advance discussion about preferred end of life care between patients/families and physicians or families' insufficient preparation for changes of patient conditions could be important reasons for late referral, as found in a previous study \[[@b14-crt-2013-148]\]. In this study, 96 patients (21.5%) underwent more than third-line chemotherapy before referral to our hospice. Considering that third-line palliative chemotherapy has no established survival benefit in most cancer patients, further treatment should be avoided, therefore, early hospice referral was appropriate for most of the patients.

In this study, in univariate analysis, male sex (p=0.027), less intake (p \< 0.02), and lower consciousness (p \< 0.005) showed an association with shorter LOS in hospice. These findings were consistent with those of previous studies \[[@b15-crt-2013-148]-[@b17-crt-2013-148]\]. Although previous studies showed that the performance status was an important factor, our study analyzed the detail factors of performance status; according to the result, intake status and consciousness were more significant factors than ambulation. Regarding laboratory results as a prognostic factor, previous studies showed that total WBC count, lymphocyte percentage, and bilirubin were significant factors \[[@b18-crt-2013-148],[@b19-crt-2013-148]\]. In our study, these factors were also statistically significant, and platelet count, serum creatinine, potassium, AST, ALT and LDH were additional significant factors affecting LOS in hospice.

In analysis of the results of multivariate analysis, intake, total WBC, platelet, creatinine, AST, ALT, and LDH were significant factors, indicating that intake status is the most important prognostic factor of performance factors. Regarding the laboratory findings, increased total WBC, decreased platelet count, increased serum creatinine, AST, ALT and increased LDH level were poor prognostic factors for survival in hospice. Increased total WBC count is related to infection or leukemoid reaction, decreased platelet count is related to sepsis or disseminated intravascular coagulopathy (DIC). Increased serum creatinine and AST, ALT level is related to decreased renal and hepatic function. Elevated LDH level is usually an indicator of high tumor burden, although it is not directly proportional to the tumor burden. All of these laboratory results are related to cancer progression and decreased overall physical function of the patient. Therefore, we strongly recommend careful evaluation of the patients' oral intake status and total WBC, platelet from complete blood count, and serum creatinine, AST, ALT, and LDH level from blood chemistry at the time of referral to hospice.

This study had some limitations. First, this study was a single center study. For greater external validity, a multicenter study is necessary. Second, because we retrospectively studied baseline characteristics we could not analyze the activity and self-care components of the PPS. In the future, conduct of a prospective controlled study is warranted in order to study palliative performance with greater detail. Third, LOS of hospice is not the sole factor influencing quality in hospice care. According to some studies, it is important for patients and their family members to be satisfied with not just the LOS in hospice but also the quality of hospice care \[[@b20-crt-2013-148]-[@b22-crt-2013-148]\]. Therefore, conduct of further research is warranted with regard to both lengthening LOS in hospice and for improving the satisfaction of patients and their families despite a short LOS in hospice.

Conclusion
==========

The LOS of hospice in our institution was too short relative to recommendations and other studies. It appears that illness progressed during the relatively long delay between diagnosis of incurable cancer and referral to hospice; consequently, by the time patients were referred to hospice their performance was poor and their overall physical function was decreased due to progression of cancer, which could have negatively affected LOS in hospice. Before hospice admission, careful evaluation of the oral intake and total WBC, platelet, creatinine, AST, ALT, and LDH level is essential because these were strong predictors of shorter LOS. In the future, we should conduct a prospective study of the subjective symptoms of patients entering hospice on affecting LOS as well as the above objective factors of the patient. In addition, investigation of the appropriate LOS in hospice for satisfaction of patients and their family members in this country is also needed.
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###### 

Baseline patient characteristics (n=446)

  Characteristic                                                            No. (%)
  ------------------------------------------------------------------------- ------------
  Age (yr)                                                                  
   \< 60                                                                    147 (33)
   ≥ 60                                                                     299 (67)
  Gender                                                                    
   Female                                                                   214 (48.0)
   Male                                                                     232 (52.0)
  Partner status                                                            
   Married or living with partner                                           39 (8.7)
   Single, divorced or widowed                                              407 (91.3)
  Referral hospital                                                         
   Tertiary referral hospital                                               214 (47.8)
   Secondary hospital                                                       232 (51.8)
  Primary diagnosis                                                         
   Gastrointestinal cancer^[a)](#tfn2-crt-2013-148){ref-type="table-fn"}^   254 (56.7)
   Thoracic cancer^[b)](#tfn3-crt-2013-148){ref-type="table-fn"}^           102 (22.8)
   Other cancers                                                            232 (51.8)
  History of chemotherapy                                                   
   First-line or second-line                                                350 (78.5)
   More than third-line                                                     96 (21.5)
  Ambulation                                                                
   Full                                                                     17 (3.8)
   Reduced                                                                  63 (14.2)
   Mainly sitting                                                           133 (29.9)
   Mainly supine                                                            120 (27.0)
   Totally bedridden                                                        112 (25.2)
  Intake                                                                    
   Full                                                                     23 (5.2)
   Reduced                                                                  137 (30.9)
   Minimal to sips                                                          173 (39.0)
   Mouth care only                                                          110 (24.8)
  Consciousness                                                             
   Full                                                                     311 (69.9)
   Confusion                                                                56 (12.6)
   Drowsy-coma                                                              78 (17.5)
  Total white blood cell count (×10^3^/μL)                                  
   \< 11,000                                                                222 (50.5)
   ≥ 11,000                                                                 218 (49.5)
  Lymphocyte (%)                                                            
   \< 12                                                                    321 (73.0)
   ≥ 12                                                                     119 (27.0)
  Hemoglobin (g/dL)                                                         
   \< 10                                                                    224 (50.2)
   ≥ 10                                                                     222 (49.8)
  Platelet (×10^3^/μL)                                                      
   ≥ 100                                                                    347 (78.5)
   \< 100                                                                   95 (21.5)
  Albumin (g/dL)                                                            
   \< 3.0                                                                   263 (59.0)
   ≥ 3.0                                                                    183 (41.0)
  Creatinine (mg/dL)                                                        
   ≥ 1.5                                                                    66 (14.8)
   \< 1.5                                                                   379 (85.2)
  Sodium (mmol/L)                                                           
   \< 135                                                                   245 (55.6)
   135-145                                                                  185 (42.1)
  Potassium (mmol/L)                                                        
   \< 3.5                                                                   56 (12.7)
   3.5-5.5                                                                  349 (79.4)
   \> 5.5                                                                   35 (7.9)
  AST (U/L)                                                                 
   \< 100                                                                   358 (80.5)
   ≥ 100                                                                    87 (19.5)
  ALT (U/L)                                                                 
   \< 100                                                                   401 (90.3)
   \> 100                                                                   44 (9.7)
  Total bilirubin (mg/dL)                                                   
   \< 1.0                                                                   227 (51.5)
   ≥ 1.0                                                                    213 (48.5)
  LDH (U/L)                                                                 
   \< 480 (upper limit of normal)                                           157 (35.2)
   ≥ 480 (upper limit of normal)                                            289 (64.8)
  CRP (mg/L)                                                                
   \< 5.0                                                                   40 (9.0)
   ≥ 5.0                                                                    402 (91.0)

AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein.

Stomach cancer, colorectal cancer, hepatobiliary cancer, pancreatic cancer,

Cancer arising in the thorax (lung cancer, esophageal cancer).

###### 

Referral time to hospice and length of survival in hospice

                                                                                                           Median days (range)
  -------------------------------------------------------------------------------------------------------- ---------------------
  Referral time to hospice from diagnosis^[a)](#tfn4-crt-2013-148){ref-type="table-fn"}^                   248 (1-4,405)
  Referral time to hospice from last anticancer treatment^[b)](#tfn5-crt-2013-148){ref-type="table-fn"}^   75 (3-1,310)
  Length of survival in hospice                                                                            9.5 (1-186)

Time interval between diagnosis of stage IV or recurrent cancer and referral to hospice,

Time interval between last anticancer treatment, including chemotherapy or radiation therapy, and referral to hospice.

###### 

Factors associated with length of survival in hospice by univariate analysis

                                    No. of patients   Median survival (day)   Hazard ratio (95% CI)   p-value
  --------------------------------- ----------------- ----------------------- ----------------------- ----------
  Age (yr)                                                                                            
   \< 60                            147               10                      1.000                   
   ≥ 60                             298               9                       1.031 (0.846-1.257)     0.760
  Gender                                                                                              
   Female                           213               13                      1.000                   
   Male                             232               8                       1.235 (1.024-1.490)     0.027
  Partner status                                                                                      
   Married or living with partner   39                14                      1.000                   
   Single or divorced or widowed    406               9                       1.123 (0.808-1.560)     0.491
  Referral hospital                                                                                   
   Tertiary hospital                214               10                      1.000                   
   Secondary general hospital       231               9                       1.013 (0.840-1.222)     0.891
  Primary diagnosis                                                                                   
   Thoracic cancer                  102               12                      1.000                   
   Gastrointestinal cancer          253               9                       0.981 (0.738-1.304)     0.894
   Other cancer                     90                9                       1.125 (0.883-1.433)     1.125
  Previous chemotherapy                                                                               
   First-line or second-line        349               10                      1.000                   
   More than third-line             96                9                       0.918 (0.732-1.151)     0.458
  Ambulation                                                                                          
   Full                             17                19                      1.000                   
   Reduced                          63                17                      1.491 (0.870-2.556)     0.146
   Mainly sitting                   133               11                      2.001 (1.200-3.337)     0.008
   Mainly supine                    120               9                       2.214 (1.324-3.700)     0.002
   Totally bedridden                111               6                       2.431 (1.453-4.067)     0.001
  Intake                                                                                              
   Full/normal                      23                19                      1.000                   
   Reduced                          137               14                      1.721 (1.099-2.695)     0.018
   Minimal to sips                  173               10                      2.063 (1.326-3.209)     0.001
   Mouth care only                  110               6                       2.811 (1.780-4.439)     \< 0.001
  Consciousness                                                                                       
   Full                             311               12                      1.000                   
   Confusion                        56                7                       1.561 (1.171-2.079)     0.002
   Drowsy-coma                      77                5                       1.685 (1.311-2.166)     \< 0.001
  Total WBC (×10^3^/μL)                                                                               
   \< 11,000                        222               12                      1.000                   
   ≥ 11,000                         218               8                       1.471 (1.205-1.796)     \< 0.001
  Lymphocyte percentage (%)                                                                           
   ≥ 12                             119               15                      1.000                   
   \< 12                            321               8                       1.574 (1.258-1.970)     \< 0.001
  Hemoglobin (g/dL)                                                                                   
   ≥ 10                             221               10                      1.000                   
   \< 10                            224               9                       1.015 (0.843-1.223)     0.872
  Platelet (×10^3^/μL)                                                                                
   ≥ 100                            347               11                      1.000                   
   \< 100                           95                8                       1.400 (1.100-1.782)     0.006
  Albumin (g/dL)                                                                                      
   ≥ 3.0                            182               12                      1.000                   
   \< 3.0                           263               9                       1.183 (0.941-1.375)     0.183
  Creatinine (mg/dL)                                                                                  
   \< 1.5                           379               10                      1.000                   
   ≥ 1.5                            66                6                       1.563 (1.181-2.069)     0.02
  Sodium (mmol/L)                                                                                     
   135-145                          185               12                      1.000                   
   \< 135                           245               9                       1.182 (0.965-1.448)     0.165
   \> 145                           10                9                       1.612 (0.821-3.167)     0.929
  Potassium (mmol/L)                                                                                  
   3.5-5.5                          349               10                      1.000                   
   \< 3.5                           56                11                      0.987 (0.735-1.324)     0.929
   \> 5.5                           35                6                       1.730 (1.193-2.511)     0.004
  AST (U/L)                                                                                           
   \< 100                           358               12                      1.000                   
   ≥ 100                            87                6                       2.146 (1.660-2.775)     \< 0.001
  ALT (U/L)                                                                                           
   \< 100                           401               11                      1.000                   
   ≥ 100                            44                4                       2.332 (1.659-3.277)     \< 0.001
  Total bilirubin (mg/dL)                                                                             
   \< 1.0                           227               12                      1.000                   
   ≥ 1.0                            213               8                       1.541 (1.258-1.888)     \< 0.001
  LDH (U/L)                                                                                           
   \< 480                           157               14                      1.000                   
   ≥ 480                            288               8                       1.420 (1.167-1.729)     \< 0.001
  CRP (mg/L)                                                                                          
   \< 5.0                           40                13                      1.000                   
   ≥ 5.0                            402               10                      1.221 (0.848-1.758)     0.283

CI, confidence interval; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein.

###### 

Factors associated with length of survival in hospice by multivariate analysis

                            Hazard ratio   95% CI        p-value
  ------------------------- -------------- ------------- ----------
  Gender                                                 
   Female                   1.000          \-            \-
   Male                     1.084          0.840-1.398   0.536
  Intake                                                 
   Full/normal              1.000          \-            \-
   Reduced                  1.525          0.924-2.517   0.099
   Minimal to sips          2.096          1.277-3.440   0.003
   Mouth care only          2.732          1.625-4.593   \< 0.001
  Consciousness                                          
   Full                     1.000          \-            \-
   Confusion                1.231          0.844-1.793   0.280
   Drowsy-coma              1.237          0.852-1.797   0.263
  Total WBC (×10^3^/μL)                                  
   ≤ 11,000                 1.000          \-            \-
   \> 11,000                1.683          1.343-2.110   \< 0.001
  Lymphocyte (%)                                         
   ≥ 12                     1.000          \-            \-
   \< 12                    1.316          0.944-1.743   0.056
  Platelet (x10^3^/μL)                                   
   ≥ 100                    1.000          \-            \-
   \< 100                   1.432          1.072-1.913   0.015
  Creatinine (mg/dL)                                     
   ≤ 1.5                    1.000          \-            \-
   \> 1.5                   1.531          1.122-2.090   0.007
  AST (U/L)                                              
   ≤ 100                    1.000          \-            \-
   \> 100                   1.425          1.034-1.964   0.030
  ALT (U/L)                                              
   ≤ 100                    1.000          \-            \-
   \> 100                   1.806          1.171-2.787   0.008
  Potassium (mmol/L)                                     
   3.5-5.5                  1.000          \-            \-
   \> 5.5                   1.191          0.803-1.766   0.385
  Total bilirubin (mg/dL)                                
   ≤ 1.0                    1.000          \-            \-
   \> 1.0                   1.190          0.948-1.494   0.134
  LDH (U/L)                                              
   \< 480                   1.000          \-            \-
   ≥ 480                    1.422          1.109-1.823   0.006

CI, confidence interval; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase.
